CLINICAL_TRIALS
trial_result
· 2017-01-30
Clinical Trial Update: BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma [Phase 3]
Summary
Phase 3 trial comparing BI 695500 to Rituxan as first-line treatment in low tumor burden follicular lymphoma was terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Lymphoma, Non-Hodgkin | Phase 3 | Status: TERMINATED | Results posted: 2017-01-30